Wave waves goodbye to its first generation
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The Huntington’s pipeline takes a blow
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Wave gets another shot at Huntington’s
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
Takeda spreads it bets in Huntington’s
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
A handful of huge gains stand out among mid and small-cap biotechs
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
Clinical developments over the Christmas period
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
Upcoming events – Gilead’s Nash refocus and an early chance for Ionis and Roche
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
